Bloomsbury Genetic Therapies develops curative treatments for rare neurological and metabolic diseases using gene therapy technologies.
Bloomsbury Genetic Therapies has raised $5.6M in total funding. The most recent round was Seed. The last funding was announced in October 2022.
Bloomsbury Genetic Therapies's investors include UCL Technology Fund.
Bloomsbury Genetic Therapies is headquartered in Cambridge, United Kingdom.
Bloomsbury Genetic Therapies develops curative treatments for rare neurological and metabolic diseases using gene therapy technologies.
Bloomsbury Genetic Therapies is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Bloomsbury Genetic Therapies — Funding & Investors." VCBacked, October 6, 2022, https://www.vcbacked.co/company/bloomsbury-genetic-therapies. Accessed August 14, 2026.
VCBacked. (2022). Bloomsbury Genetic Therapies — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/bloomsbury-genetic-therapies
{{cite web |title=Bloomsbury Genetic Therapies — Funding & Investors |url=https://www.vcbacked.co/company/bloomsbury-genetic-therapies |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated